Acetylcysteine for the prevention of radiocontrast-induced nephropathy

Minerva Cardioangiologica

Volumn 51, Issue 5, 2003, Pages 525-530

  Tepel, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acetylcysteine; Contrast media, adverse effects; Kidney diseases, prevention and control; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; DIATRIZOATE; IODIXANOL; IOHEXOL; IONIC CONTRAST MEDIUM; NONIONIC CONTRAST MEDIUM; REACTIVE OXYGEN METABOLITE;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; HYDRATION; KIDNEY DISEASE; NEPHROTOXICITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RADIOCONTRAST INDUCED NEPHROPATHY; REVIEW; RISK MANAGEMENT;

ACETYLCYSTEINE; CONTRAST MEDIA; FREE RADICAL SCAVENGERS; HEPATITIS, TOXIC; HUMANS;

EID: 0348050061     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Contrast media-associated nephrotoxicity. Curr Opin Nephrol Hypertens 1996;5:127-33.
2. Tublin ME, Murphy ME, Tessler FN. Current concepts in contrast media-induced nephropathy. AJR Am J Roentgenol 1998;171:933-9.
3. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000;11:177-82.
4. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990;150:1237-42.
5. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75.
6. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36:1542-8.
7. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;275:1489-94.
8. Katholi RE, Woods WT Jr, Taylor GJ, Deitrick CL, Womack KA, Katholi CR et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998;32:64-71.
9. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990;258:F115-F20.
10. Parvez Z, Rahman MA, Moncada R. Contrast media-induced lipid peroxidation in the rat kidney. Invest Radiol 1989;24:697-702.
11. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF et al. Nephrotoxicity of ionic and nonionic contrast media in 1 196 patients: a randomized trial. The lohexol Cooperative Study. Kidney Int 1995;47:254-61.
12. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993;188:171-8.
13. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxicity in high-risk patients study of iso-osmolar and low-osmolar non-ionic contrast media study investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-9.
14. Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography can be avoided with hydration. AJR Am J Roentgenol. 1981;136:859-61.
15. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-20.
16. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1 620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-36.
17. Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 1998;114:1570-4.
18. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
19. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002;89:356-8.
20. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-8.
21. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40:298-303.
22. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-83.
23. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002;62:2202-7.
24. Boccalandro F, Amhad M, Smalling RW, Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003;58:336-41.
25. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003;289:553-8.
26. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003;41:2114-8.
27. Adamian MG, Moussa I, Mehran R, Dangas G, Farkhou M, Adayan Y et al. The role of mucomyst administration prior to percutaneous interventions on renal function in patients with chronic renal failure. American College of Cardiology Meeting 2002; http://www.acc.org/2002ann_meeting/abstract_02.htm
28. Tadros GM, Mouhayar EN, Akinwande AO, Campbell B, Wood C, Blankenship JA. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invasive Cardiol 2003;15:311-4.
29. Izzedine H, Guerin V, Launay-Vacher V, Bernard M, Deray G. Effect of N-acetylcysteine on serum creatinine level. Nephrol Dial Transplant 2001;16:1514-5.
30. Wang A, Holcslaw T, Bashore TM, Freed MI, Miller D, Rudnick MR et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000;57:1675-80.
31. Katholi RE, Taylor GJ, McCann WP, Woods WT Jr, Womack KA, McCoy CD et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995;195:17-22,
32. Huber W, Schipek C, Ilgmann K, Page M, Hennig M, Wacker A et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003;91:1157-62.
33. Sketch MH Jr, Whelton A, Scholhnayer E, Koch JA, Bernink PJ, Woltering F et al. Prostaglandin E1 Study Group. Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study. Am J Ther 2001;8:155-62.
34. Borgstrom L, Kagedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 1986;31:217-22.
35. Townsend DM, Tew KD, Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother 2003;57:145-55.
36. Dickinson DA, Forman HJ. Cellular glutathione and thiols metabolism. Biochem Pharmacol 2002;64:1019-26.
37. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R. N-acetylcysteine ameliorates ischemic renal failure. Am J Physiol 1997;272:F292-F8.
38. Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol 2001;37:117-23.
39. Ichiki T, Takeda K, Tokunou T, Funakoshi Y, Ito K et al. Reactive oxygen species-mediated homologous downregulation of angiotensin II type 1 receptor mRNA by angiotensin II. Hypertension 2001;37:535-40.
40. Frank, GD, Eguchi S, Inagami T, Motley ED. N-acetylcysteine inhibits angiotensin II-mediated activation of extracellular signal-regulated kinase and epidermal growth factor receptor. Biochem Biophys Res Commun 2001;280:1116-9.